| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject new compound having therapeutic and preventive effects for psychiatric disorders such as schizophrenia, anxiety, and related diseases and depression, and neurological diseases such as drug dependence, cognitive disorders and Alzheimer's disease, and useful as a metabotropic glutamic acid receptor agonist. SOLUTION: This new compound is shown by formula I (X<1> is H or the like; R<1> and R<2> are each H or the like), pref. (1S,2S,3S,5R,6S)-2-amino-3- fuorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid. The compound of formula I is obtained, for example, by the following steps: a ketone form of formula II (R<3> is a 1-10C lower alkyl) e.g. (1SR,5RS,6SR)ethyl 2- oxobicyclo[3.1.0]hexane-6-carboxylate} as the starting material is subjected to fluorination, conversion-to-hydantoin by Bucherer-Bergs reaction, diastereomer separation, ester site hydrolysis, resolution, and hydantoin site hydrolysis, successively in the order. |
